[go: up one dir, main page]

BRPI0720118B8 - forma sólida de dosagem farmacêutica para administração oral compreendendo cloridrato de valganciclovir - Google Patents

forma sólida de dosagem farmacêutica para administração oral compreendendo cloridrato de valganciclovir

Info

Publication number
BRPI0720118B8
BRPI0720118B8 BRPI0720118A BRPI0720118A BRPI0720118B8 BR PI0720118 B8 BRPI0720118 B8 BR PI0720118B8 BR PI0720118 A BRPI0720118 A BR PI0720118A BR PI0720118 A BRPI0720118 A BR PI0720118A BR PI0720118 B8 BRPI0720118 B8 BR PI0720118B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical dosage
oral administration
solid pharmaceutical
dosage form
valganciclovir hydrochloride
Prior art date
Application number
BRPI0720118A
Other languages
English (en)
Inventor
Howard Infeld Martin
Oksana Bachynsky Maria
Hargovindas Shah Navnit
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39410167&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0720118(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0720118A2 publication Critical patent/BRPI0720118A2/pt
Publication of BRPI0720118B1 publication Critical patent/BRPI0720118B1/pt
Publication of BRPI0720118B8 publication Critical patent/BRPI0720118B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

formulação em pó para valganciclovir. a presente invenção refere-se a novas formas de dosagem farmacêutica sólida de cloridrato de valganciclovir para administração oral, após serem constituídas em água. estas formas de dosagem farmacêutica são úteis no tratamento ou controle de vírus, tais como herpes simplex e citomegalovírus.
BRPI0720118A 2006-12-13 2007-12-03 forma sólida de dosagem farmacêutica para administração oral compreendendo cloridrato de valganciclovir BRPI0720118B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87463406P 2006-12-13 2006-12-13
US60/874,634 2006-12-13
PCT/EP2007/063151 WO2008071573A2 (en) 2006-12-13 2007-12-03 Powder formulation for valganciclovir

Publications (3)

Publication Number Publication Date
BRPI0720118A2 BRPI0720118A2 (pt) 2014-01-14
BRPI0720118B1 BRPI0720118B1 (pt) 2020-11-17
BRPI0720118B8 true BRPI0720118B8 (pt) 2021-05-25

Family

ID=39410167

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720118A BRPI0720118B8 (pt) 2006-12-13 2007-12-03 forma sólida de dosagem farmacêutica para administração oral compreendendo cloridrato de valganciclovir

Country Status (31)

Country Link
US (6) US20080146591A1 (pt)
EP (1) EP2101733B1 (pt)
JP (1) JP5111517B2 (pt)
KR (1) KR101116553B1 (pt)
CN (1) CN101541310B (pt)
AR (1) AR065541A1 (pt)
AU (1) AU2007332640B2 (pt)
BR (1) BRPI0720118B8 (pt)
CA (1) CA2671470C (pt)
CL (1) CL2007003564A1 (pt)
CO (1) CO6220902A2 (pt)
CR (1) CR10822A (pt)
DK (1) DK2101733T3 (pt)
ES (1) ES2391912T3 (pt)
HR (1) HRP20121033T1 (pt)
IL (1) IL198854A (pt)
MA (1) MA31280B1 (pt)
MX (1) MX2009005921A (pt)
MY (1) MY152540A (pt)
NO (1) NO339838B1 (pt)
NZ (1) NZ577179A (pt)
PE (1) PE20081578A1 (pt)
PL (1) PL2101733T3 (pt)
PT (1) PT2101733E (pt)
RS (1) RS52457B (pt)
RU (1) RU2440118C2 (pt)
SI (1) SI2101733T1 (pt)
TW (1) TWI341730B (pt)
UA (1) UA93599C2 (pt)
WO (1) WO2008071573A2 (pt)
ZA (1) ZA200903840B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513433A (ja) * 2008-03-07 2011-04-28 レイ ダブリュー． エクスレイ， ヘルペスウイルス関連疾患の処置
CN102048677B (zh) * 2009-11-09 2014-03-05 杭州赛利药物研究所有限公司 一种盐酸缬更昔洛韦固体制剂及其制备方法
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
IN2014MN02105A (pt) * 2012-04-20 2015-09-11 Annji Pharm Co Ltd
WO2014106962A1 (ko) 2013-01-07 2014-07-10 삼아제약 주식회사 향상된 용해도를 갖는 신규한 속용성 과립제형
WO2015016789A1 (en) * 2013-08-02 2015-02-05 Ali Raif İlaç Sanayi Ve Ticaret Anonim Şirketi Powder formulation of valganciclovir
CN104055746B (zh) * 2014-07-12 2017-06-30 河北仁合益康药业有限公司 一种盐酸缬更昔洛韦包衣片剂组合物
RU2720805C1 (ru) * 2019-05-22 2020-05-13 Общество с ограниченной ответственностью "Трейдсервис" Фармацевтическая композиция валганцикловира
EP3976198A4 (en) 2019-05-31 2023-07-19 Viracta Subsidiary, Inc. METHODS OF TREATING VIRUS-ASSOCIATED CANCERS WITH HISTONE DEACETYLASE INHIBITORS
CN110613718A (zh) * 2019-09-19 2019-12-27 湖北科益药业股份有限公司 一种缬更昔洛韦组合物
CN110934823B (zh) * 2019-12-27 2022-03-01 湖北康源药业有限公司 一种盐酸缬更昔洛韦口服溶液及制备方法
WO2021161317A1 (en) * 2020-02-12 2021-08-19 Cts Chemical Industries Ltd. Stable pharmaceutical compositions comprising valgancyclovir and uses thereof
CN114028347B (zh) * 2021-11-30 2023-05-12 海南皇隆制药股份有限公司 注射用帕瑞昔布钠及其制备方法
CN115569113B (zh) * 2022-09-19 2023-11-10 江苏汉晨药业有限公司 一种盐酸缬更昔洛韦口服溶液

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU191542B (en) 1983-04-08 1987-03-30 Boehringer Ingelheim Ltd Process for production of pastiles containing dipyridamel independent from ph with regulated output of the active substance
US5856481A (en) 1994-07-28 1999-01-05 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US5840890A (en) 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
JP2001518493A (ja) * 1997-10-03 2001-10-16 スミスクライン・ビーチャム・コーポレイション 炭酸リチウムの放出制御性固体投与形
US6221917B1 (en) * 1997-12-30 2001-04-24 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
CA2244097A1 (en) * 1998-08-21 2000-02-21 Bernard Charles Sherman Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid
US20020143058A1 (en) * 2001-01-24 2002-10-03 Taro Pharmaceutical Inductries Ltd. Process for preparing non-hygroscopic sodium valproate composition
ATE382338T1 (de) * 2003-03-19 2008-01-15 Jordanian Pharmaceutical Mfg Nicht-hygroskopische pharmazeutische zusammensetzungen die nicht hydratisierte quinolon-carbonsäure enthalten
EP1660499A1 (en) * 2003-08-28 2006-05-31 Ranbaxy Laboratories Limited Amorphous valganciclovir hydrochloride
DE602005008721D1 (de) * 2004-03-10 2008-09-18 Ranbaxy Lab Ltd Verfahren zur herstellung von festen dosierformen von amorphem valganciclovir-hydrochlorid
BRPI0614870A2 (pt) 2005-08-22 2011-04-19 Novartis Ag composições farmacêuticas

Also Published As

Publication number Publication date
PT2101733E (pt) 2012-10-30
CA2671470C (en) 2012-05-01
AU2007332640B2 (en) 2011-04-07
MY152540A (en) 2014-10-15
TW200840585A (en) 2008-10-16
US20170266286A1 (en) 2017-09-21
MA31280B1 (fr) 2010-04-01
EP2101733A2 (en) 2009-09-23
NO339838B1 (no) 2017-02-06
ES2391912T3 (es) 2012-12-03
NO20092254L (no) 2009-07-09
SI2101733T1 (sl) 2012-12-31
US20150057296A1 (en) 2015-02-26
CO6220902A2 (es) 2010-11-19
AU2007332640A1 (en) 2008-06-19
US9642911B2 (en) 2017-05-09
RS52457B (en) 2013-02-28
PE20081578A1 (es) 2008-11-12
CN101541310A (zh) 2009-09-23
US20180153998A1 (en) 2018-06-07
IL198854A0 (en) 2010-02-17
RU2009126616A (ru) 2011-01-20
KR20090086469A (ko) 2009-08-12
US11185588B2 (en) 2021-11-30
WO2008071573A3 (en) 2008-11-27
PL2101733T3 (pl) 2013-02-28
UA93599C2 (en) 2011-02-25
US20130150382A1 (en) 2013-06-13
JP5111517B2 (ja) 2013-01-09
EP2101733B1 (en) 2012-09-26
NZ577179A (en) 2011-12-22
AR065541A1 (es) 2009-06-17
WO2008071573A2 (en) 2008-06-19
KR101116553B1 (ko) 2012-03-13
CN101541310B (zh) 2012-11-07
BRPI0720118A2 (pt) 2014-01-14
JP2010513237A (ja) 2010-04-30
IL198854A (en) 2014-06-30
HRP20121033T1 (hr) 2013-01-31
BRPI0720118B1 (pt) 2020-11-17
US8889109B2 (en) 2014-11-18
MX2009005921A (es) 2009-06-17
DK2101733T3 (da) 2013-02-04
CR10822A (es) 2009-06-25
US20190117775A1 (en) 2019-04-25
US20080146591A1 (en) 2008-06-19
RU2440118C2 (ru) 2012-01-20
CA2671470A1 (en) 2008-06-19
CL2007003564A1 (es) 2008-07-18
ZA200903840B (en) 2010-03-31
TWI341730B (en) 2011-05-11

Similar Documents

Publication Publication Date Title
BRPI0720118B8 (pt) forma sólida de dosagem farmacêutica para administração oral compreendendo cloridrato de valganciclovir
IL274602A (en) Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and use thereof in the preparation of medicaments for treating thrombocytopenia
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
PH12015500758A1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
PH12015502780A1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
IL199152A (en) Annals 2 - (piperidine-4-ram) -4-phenoxy or phenylamino-pyrimidine, containing and containing pharmaceutical preparations for the preparation of viral infections
BR112013025987A2 (pt) derivados de pirimidina para o tratamento de infecções virais
BR112015015898A8 (pt) composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
MX2010014057A (es) Compuestos de piridina.
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
BR112015018168A2 (pt) inibidores de rock suaves
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
IL177658A0 (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
BRPI0911678B8 (pt) maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central
IL210975A (en) Annapomapungin History, Pharmaceuticals Containing Them and Their Use in Preparing Medicines to Treat Fungal Infections
WO2010085924A3 (en) Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds
CL2007001857A1 (es) Compuestos derivados del acido fenil-acetico, inhibidores de cox-2; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, osteoartritis, dolor, entre otras.
IL192820A (en) Dimeric derivatives of indoloquinoxaline, process for the preparation thereof, pharmaceutical compositions comprising them and uses thereof in the manufacture of medicaments for the treatment of viral infections
TR201100151A2 (tr) İbandronate formülasyonu.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/12/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: CHEPLAPHARM ARZNEIMITTEL GMBH (DE)